Endocrine-exocrine Functions and Prognosis After Pancreatectomy

February 5, 2026 updated by: National Taiwan University Clinical Trial Center, National Taiwan University Hospital

The Analysis of Endocrine-exocrine Functions and Prognosis After Pancreatectomy

Pancreatic diseases often require surgery or invasive procedures to provide a chance for a cure. However, due to the pancreas's unique anatomical structure, its relative position to adjacent organs, and its dual endocrine and exocrine functions, the complexity of surgery is increased, impacting the patient's postoperative quality of life. Therefore, this project aims to retrospectively collect basic data, preoperative and postoperative blood tests (blood cell counts, biochemistry, tumor markers, glucose-related, lipid-related), and preoperative and postoperative imaging examinations (CT, MRI, Ultrasound, PET scan, Endoscopy, etc.) of patients who underwent pancreatic surgery at our hospital. We aim to compare whether surgical methods, lesion margin clearance rates, and postoperative remnant pancreatic volume affect the patient's endocrine function, exocrine function, quality of life, and disease prognosis. This analysis is intended to understand the indications, surgery-related factors, and prognosis for patients planning to undergo pancreatic surgery, with the expectation of providing more diverse and specific treatment recommendations for patients with pancreatic diseases in the future

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

3500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Taiwan
    • Taiwan
      • Taipei, Taiwan, Taiwan, 10002
        • Recruiting
        • National Taiwan University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients received pancreatectomy at National Taiwan University Hospital after 2017

Description

Inclusion Criteria:

  • All patients scheduled for pancreatectomy

Exclusion Criteria:

  • Age under 20 years or older than 75 years; Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
pancreatectomy group
Procedure: pancreatectomy
all procedures demanding pancreatic parenchyma transaction

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
postoperative pancreatic endocrine-exocrine functions
Time Frame: 6 months after pancreatectomy
  1. Pancreatic endocrine function will be measured by incidence of appearance of new-onset or aggravated DM after operation.
  2. pancreatic exocrine function will be measured by incidence of appearance of steatorrhea which can be alleviated by replacement of digestive enzyme.
6 months after pancreatectomy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Estimated)

December 31, 2034

Study Completion (Estimated)

December 31, 2034

Study Registration Dates

First Submitted

January 22, 2026

First Submitted That Met QC Criteria

February 5, 2026

First Posted (Actual)

February 9, 2026

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 202107131RINC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Neoplasm

Clinical Trials on pancreatectomy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe